Organon OGN Europe and Canada — Concentration risk
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Organon in its filing.
Tagged under the XBRL concept us-gaap:ConcentrationRiskPercentage1.
The official record: Organon’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Organon's europe and canada — concentration risk.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Organon's europe and canada — concentration risk?
- Organon (OGN) reported europe and canada — concentration risk of 18.8% in Q4 2025.
- How has Organon's europe and canada — concentration risk changed year-over-year?
- Organon's europe and canada — concentration risk increased by 5.6% year-over-year, from 17.8% to 18.8%.
- What is the long-term trend for Organon's europe and canada — concentration risk?
- Over 4 years (2021 to 2025), Organon's europe and canada — concentration risk has grown at a -1.6% compound annual growth rate (CAGR), from 80% to 75%.
- What does europe and canada — concentration risk mean?
- This metric quantifies the degree of reliance on a limited number of products, customers, or therapeutic areas within the Europe and Canada geographic segment. A higher value indicates increased exposure to potential revenue volatility should specific key products underperform or face competitive pressure. Monitoring this risk is essential for assessing the diversification and long-term sustainability of the regional revenue base.